Biofrontera reports Q1 2020 financial results
Leverkusen, May 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today
reported its financial results for the first quarter ended March 31, 2020 and provided an update on recent developments.
Key financial figures and business performance in Q1 2020
EUR thousands |
3M 2020 |
3M 2019 |
Change |
Total revenue | 6,473 | 6,808 | (5%) |
Research and development costs | (1,311) | (1,088) | 21% |
General administrative costs | (2,232) | (1,974) | 13% |
Sales costs | (8,698) | (5,554) | 57% |
Loss before tax | (5,498) | (2,637) | 109% |
Loss after tax | (6,082) | (2,980) | 105% |
For the period from January 1 to March 31, 2020, consolidated sales of 6.5 million euros reflect a decrease of 5% compared to the same period last year. This was due to the COVID-19 pandemic, which
had a significant negative impact on business development. We experienced the most significant impact of the COVID-19 pandemic in the USA. While we were able to achieve product sales of 4.2 million
euros in our largest market in the first quarter, this represents a decline in sales of 19% compared to 5.2 million euros in the same period last year. In early 2020, sales were slightly lower than
expected due to stockpiling of Ameluz by doctors at the end of 2019 prior to the price increase effective as of January 1, 2020. Between mid-February and mid-March 2020, we were then able to
generate sales revenues in line with our original budget. However, due to the coronavirus crisis in the second half of March, revenue dropped close to zero.
Lesen Sie auch
Sales in Germany kicked off the new year strongly, clearly exceeding our expectations. Despite falling sales figures in March, product sales in the first quarter of 2020 rose by 22% to EUR 1.3 million, compared to EUR 1.1 million in the first quarter of 2019. Sales generated in the rest of Europe amounted to approximately EUR 0.8 million, compared to EUR 0.6 million in the same period last year. This increase was due to higher shipments to license partners, but in particular to the sales revenues generated in Spain. Revenue growth was exceptionally strong prior to the strict lockdown restrictions introduced in Spain due to the COVID-19 pandemic, which makes us confident that revenue will recover quickly once the restrictions are lifted.